Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. - Wikidata - wikimedia - TriplyDB

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.

http://www.wikidata.org/entity/Q38034394

about

Interventions for chronic palmoplantar pustulosis Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview Ustekinumab for the treatment of Crohn's disease.Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement Treatment of nail psoriasis: common concepts and new trends Psoriasiform Eruption and Worsening of Pustulosis Palmoplantaris After Treatment with Two Anti-TNF-α Inhibitors, Followed by Successful Treatment with Ustekinumab.Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.Paradoxical effects of anti-TNF-α agents in inflammatory diseases.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.The safety of ustekinumab for the treatment of psoriatic arthritis.Erythrodermic psoriasis: current and future role of biologicals.Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis.Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis.Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.

P2860

Q24186928-92A459E1-C215-4395-BC30-0772D6EFFD44 Q26738918-D2D7BB0F-3B38-4972-B8B7-A69476BBE345 Q30390909-92093EAC-DB9C-45F6-8FCA-128B7B35B4E2 Q30620977-922A6C32-640A-46AF-8097-1B38F0262BFA Q34769284-D955C830-0045-4AB2-9D30-C30B9137CA53 Q37432268-2811CBA1-E019-4A22-8F03-2E15BAB0FA3D Q38161956-B4427DC4-2938-47D7-920C-A0F53C6343CB Q38170158-205B2B16-2779-441A-9AE2-6B5E119DED65 Q38394816-C9C2AA0E-C0C4-4D8C-A44F-7BBB43E01B51 Q38820480-64ABB71F-6418-4686-9706-14C2E48E7641 Q39031386-17CF207D-CE5A-4FA6-B5B5-448856A5AE15 Q42319958-3174F647-BFEB-4142-89CE-78163C804819 Q44889491-DED421EE-EEB8-41FE-B357-096EFF0C439A Q53118369-BBB5EF32-EA6E-4DFC-ACAF-34C373C1F37B

P2860

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.

http://www.wikidata.org/entity/Q38034394

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Ustekinumab treatment of TNF a ...... ritis: case report and review.

@en

type

label

Ustekinumab treatment of TNF a ...... ritis: case report and review.

@en

prefLabel

Ustekinumab treatment of TNF a ...... ritis: case report and review.

@en

P1433

Q38034394-9F0F14F6-78AB-47C8-91AC-427B8AA417C8

P1476

Q38034394-279F238A-F5F9-4FCF-B161-508954254DFA

P2093

Q38034394-46D5A687-4D89-4E0C-8AB6-970694233F2A

Q38034394-A3346EAD-CDE8-41CE-95E9-CC659CE17FFD

Q38034394-D5F6C2A0-583F-4CFE-B2B0-5F365A1F5B38

P2860

Q38034394-1A270717-D28D-4BCB-AF6E-91C0122A4DA4

Q38034394-1E58F62F-EB32-4155-9806-DE922DA14C6F

Q38034394-583B892E-397E-47A2-906A-D10E999215CB

Q38034394-67FCCFB9-E78C-4814-B034-53C5FB2023A3

Q38034394-84F7B6B4-B242-409C-9CC7-A9F308BB3980

Q38034394-8BF43621-903C-475F-8DAB-13BC6D22ED60

Q38034394-8F60F739-5459-4C24-AEBB-2F92E53FF24D

Q38034394-9CAA0CC4-5471-415F-A48D-084D028AF072

Q38034394-AD0A824E-7038-44E0-80F6-7B6B01C2573D

Q38034394-B52968B5-5BD4-4BC0-B26E-AE5ED7855B08

P304

Q38034394-B0A2A481-B6B0-4953-858D-7CA479A4B80C

P31

Q38034394-A60A2495-2B09-42E8-B8A6-4FD8E0D5BF66

P356

Q38034394-50045879-011A-4EE9-ADB5-87207A5FCCBC

P433

Q38034394-FAE4323A-DA89-4DB5-9C7C-98397A597665

P478

Q38034394-742AB1D5-FD96-4959-AFAE-B1BAF68BBF09

P50

Q38034394-6DFC4294-8DF7-4552-84D4-19AC1A3263B1

P577

Q38034394-5BC07599-9EAF-4476-B202-BB5BFC638564

P698

Q38034394-0909622E-B181-44D6-8CCE-F13FCF618E94

P921

Q38034394-D9C3FAC0-3C60-4AD2-9B3C-3B6FD0A92C6B

P356

P1433

P1476

Ustekinumab treatment of TNF a ...... ritis: case report and review.

@en

P2093

Anna López-Ferrer

http://www.w3.org/2001/XMLSchema#string

Caridad E Morales-Múnera

http://www.w3.org/2001/XMLSchema#string

Carme Geli

http://www.w3.org/2001/XMLSchema#string

P2860

Cross-regulation of TNF and IFN-alpha in autoimmune diseases

Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases.

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.

Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab.

Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.

P304

14-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000339864

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

225

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22890275

http://www.w3.org/2001/XMLSchema#string

P921